News | May 29, 2007

Doctor Technique a Possible Factor in DES-Related Thrombosis

May 30, 2007 -- As concern and investigation continue concerning the link between drug-eluting stents and late-stent thrombosis, focus is now turning to the issue of improperly implanted stents by physicians. "The Wall Street Journal" reports this week that cardiologists' overconfidence in the benefits of drug-coated stents may have contributed to sloppy technique.

A recent study sponsored by a stent maker, states the Journal, found that two-thirds of the stents were implanted incorrectly.

In response, the Cardiovascular Research Foundation, a prominent advocate of stent technology, is launching an 11,000-patient study that is designed in part to examine whether less-than-optimal deployment of a stent is linked to the type of clots at the center of the debate, those that occur more than a year after implantation.

"We went through a period with drug-eluting stents thinking that it might not be so important to put them in perfectly," says Kirk Garratt, cardiologist at Lenox Hill Hospital, New York. "There was so much optimism and confidence about the stents that people might have gotten a little lazy," he says. Dr. Garratt and the other cardiologists quoted in this article consult for or get research-grant support or speaking fees from companies that make products used in stent procedures; in some cases, grants or fees are paid to the institution and not directly to the doctor.

The clotting problem, known as very late thrombosis, is rare, occurring in probably less than 0.5 percent of the roughly one million stent procedures done in the U.S. each year. But it happens long after doctors have believed patients were out of such danger, and the result is often either death or a major heart attack. The chief remedy is to keep patients for at least a year on both aspirin and a second drug called Plavix to prevent clots. But cost and bleeding risks are among the drawbacks to that strategy.

The Journal adds that not all experts agree that physician technique is a big culprit, and that most believe very late thrombosis has multiple contributors. Gary Mintz, a cardiologist at Cardiovascular Research Foundation, says that over time, the body's healing process covers over the stent, as well as placement shortcomings. "The effect of poor technique diminishes as time gets longer from implantation," he says.

The complete Wall Street Journal article, dated May 29, is available at www.wsj.com, or contact the authors at: [email protected] and [email protected]

Related Content

Titanium-Nitride-Oxide Stent Superior to Bioabsorbable DES in Acute Coronary Syndrome Patients

Image courtesy of Hexacath

News | Stents Drug Eluting | May 31, 2018
Late-breaking trial results presented at the EuroPCR Congress, May 21-24 in Paris, France, found the Optimax titanium-...
Orsiro DES Shows Lowest Two-Year Target Lesion Failure in BIO-RESORT Trial
News | Stents Drug Eluting | May 31, 2018
Two-year outcome data from the BIO-RESORT randomized controlled trial were presented in a late-breaking clinical trials...
OCT Reveals Excellent Healing Profile for Complex CAD Patients With Resolute Onyx DES
News | Stents Drug Eluting | May 29, 2018
Investigators recently unveiled clinical data from the independently run Onyx 1-Month OCT Study showing strong early...
Abbott's Xience Sierra Stent Receives FDA Approval
Technology | Stents Drug Eluting | May 25, 2018
Abbott announced it received approval from the U.S. Food and Drug Administration (FDA) for Xience Sierra, the newest...
Medtronic Launches 2 mm Onyx DES
Technology | Stents Drug Eluting | February 26, 2018
February 26, 2018 – Designed specifically for small vessels, Medtronic plc announced U.S.
Detroit Medical Center Heart Hospital Uses Michigan's First EluNIR Drug-Eluting Stent
News | Stents Drug Eluting | February 19, 2018
February 19, 2018 — The Detroit Medical Center’s (DMC) interventional cardiology team at Heart Hospital recently beca
Biotronik Symposium Highlights Differing Roles of Drug-Eluting Stents and Magnesium Scaffolds in Clinical Practice
News | Stents Drug Eluting | January 25, 2018
January 25, 2018 – Data presented at the Biotronik-sponsored...
The Abbott Absorb Bioresorbable Vascular Scaffold (BVS) bioabsorbable stent.

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS).

Feature | Stents Drug Eluting | January 17, 2018 | Dave Fornell
There was no shortage of interest in bioresorbable stent technologies at the many sessions offered on this topic or b
Cordis and Medinol Announce FDA Approval of EluNIR Drug-Eluting Stent System
Technology | Stents Drug Eluting | December 13, 2017
Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug Administration (FDA) approval of...
The Xience Sierra stent.
Technology | Stents Drug Eluting | November 09, 2017
November 9, 2017 — Abbott received European CE mark for Xience Sierra, the newest generation of the company's Xience
Overlay Init